UroGen Pharma Ltd. URGN revenue by segment, product and geography
In its fiscal year ending 2025-12-31, UroGen Pharma Ltd. reported revenue across 2 products and services; the largest, Jelmyto, was $94M, 85.6% of the filed sum (+4.0% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Jelmyto$94M85.6%+4.0% yoy
- Zusduri$15.8M14.4%no prior
Members sum to the consolidated $110M for this period.
- Zusduri$29.2M57.4%no prior
- Jelmyto$21.7M42.6%+7.2% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.